BioNTech SE (NASDAQ:BNTX) Sees Significant Drop in Short Interest

BioNTech SE (NASDAQ:BNTX) saw a large drop in short interest in June. As of June 15th, there was short interest totalling 2,740,000 shares, a drop of 9.9% from the May 31st total of 3,040,000 shares. Currently, 1.2% of the company’s stock are sold short. Based on an average trading volume of 718,500 shares, the short-interest ratio is presently 3.8 days.

Institutional Trading of BioNTech

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC grew its stake in shares of BioNTech by 121.0% in the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after purchasing an additional 150 shares during the last quarter. CWM LLC grew its stake in shares of BioNTech by 657.6% in the 4th quarter. CWM LLC now owns 250 shares of the company’s stock worth $26,000 after purchasing an additional 217 shares during the last quarter. Frazier Financial Advisors LLC acquired a new position in shares of BioNTech in the 4th quarter worth approximately $30,000. First Horizon Advisors Inc. acquired a new position in shares of BioNTech in the 4th quarter worth approximately $38,000. Finally, Covestor Ltd increased its position in shares of BioNTech by 47.2% in the first quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after acquiring an additional 133 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors.

BioNTech Price Performance

Shares of BNTX stock traded down $1.53 during midday trading on Monday, reaching $78.83. 887,003 shares of the company were exchanged, compared to its average volume of 718,521. BioNTech has a 12 month low of $78.68 and a 12 month high of $125.83. The company has a market cap of $18.74 billion, a P/E ratio of 157.60 and a beta of 0.23. The company’s 50 day moving average price is $92.22 and its two-hundred day moving average price is $94.66. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.16 and a current ratio of 11.38.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, May 6th. The company reported ($1.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.60). BioNTech had a return on equity of 0.55% and a net margin of 4.01%. The company had revenue of $203.69 million for the quarter, compared to the consensus estimate of $589.96 million. On average, sell-side analysts expect that BioNTech will post -2 earnings per share for the current year.

Analyst Upgrades and Downgrades

BNTX has been the subject of several recent analyst reports. BMO Capital Markets decreased their price objective on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a report on Tuesday, May 7th. HC Wainwright reaffirmed a “buy” rating and issued a $113.00 price target on shares of BioNTech in a report on Wednesday, June 26th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $171.00 price target on shares of BioNTech in a report on Thursday, March 21st. UBS Group decreased their price target on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a report on Wednesday, March 27th. Finally, TD Cowen lifted their price target on shares of BioNTech from $95.00 to $98.00 and gave the company a “hold” rating in a report on Tuesday, May 7th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $111.70.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.